Announcements Trials

Conditions

Genitourinary 2Dermatologic 1Gynecologic 1

Drug Classes

Anti-PD-1 12BRAF inhibitor 4MEK inhibitor 3Anti-PD-L1 2Anti-HER2 ADC 1Bispecific gp100 peptide-HLA-directed CD3 T-cell engager 1Mononuclear cell vaccine 1Multi-ingredient 1Nitrogen mustard 1RET inhibitor 1ROS1 inhibitor 1TRK inhibitor 1
Multi-ingredient × Dermatologic × Clear all

1 Announcement

2022-03-18

FDA approves Opdualag for unresectable or metastatic melanoma

Trial
RELATIVITY-047
Drug
Opdualag (nivolumab and relatlimab-rmbw) · Multi-ingredient
Condition
Dermatologic
Data powered by HemOnc (CC BY 4.0) Colophon âš¡